Overview
Tirzepatide engages both GIP and GLP-1 receptors, offering a dual-incretin approach used in many contemporary weight-management and metabolic programs under licensed supervision.
Label-first clinic supply presentation
PenFeaturedIn stock
Strength
45mg/ 3ml
Total API
135 mg
Form
Pen
Brand
PureVital
GLP Weight Loss Pens
Tirzepatide Pen
Dual GIP/GLP-1 agonist for advanced metabolic clinics
PV-TIRZEPATIDE-PEN-45MG3ML
Professional price
$383.99
Tirzepatide engages both GIP and GLP-1 receptors, offering a dual-incretin approach used in many contemporary weight-management and metabolic programs under licensed supervision. Presentation: 45mg/ 3ml (Pen); total API 135 mg. For licensed clinics and practitioners.
- Dual GIP/GLP-1 agonist for advanced metabolic clinics
- Strength: 45mg/ 3ml
- Total API: 135 mg
- Pen presentation for licensed clinic programs
Licensed clinic formulary
Label-first SKU detail
Wholesale & bulk desk
PureVital Clinical Formulary — Strength & Volume updates April 2026
Mechanism themes
Receptor and pathway context written for clinic teams.
Clinic-use references
Titration and presentation notes — not patient prescriptions.
Safety & regulatory
Precautions, interactions, and status framing in one monograph.
Clinical monograph
Professional product details
Dual GIP/GLP-1 agonist for advanced metabolic clinics. Structured for licensed clinics — mechanism, clinic-use themes, safety, and package clarity in one place.
Compound family
tirzepatide
Contents of the package
What arrives for this PureVital SKU
- 1 × 45mg/ 3ml pen presentation
- Active listing: Tirzepatide Pen
- Total API (label): 135 mg
- SKU PV-TIRZEPATIDE-PEN-45MG3ML
- For parenteral clinic use as directed by the licensed prescriber
- PureVital professional clinical formulary supply
About Tirzepatide
Dual agonism can deliver robust appetite and glycemic effects in appropriate patients. PureVital stocks vial, pen, and sublingual presentations so clinics can match route to adherence.
Mechanism of action
- GIP receptor activity supports metabolic signaling alongside GLP-1
- GLP-1 pathway contributes to satiety and slowed gastric emptying
- Combined incretin tone is used in structured titration programs
Clinic use & titration (professional reference)
01
Start low
02
Assess GI
03
Escalate
04
Maintain
Programs commonly escalate weekly doses in steps as tolerated. Confirm concentration and pen/vial markings before each dispense.
- Assess GI tolerability before each escalation
- Coordinate nutrition support during rapid weight-change phases
- Document indication, consent, and monitoring in the clinic chart
Adverse reactions & precautions
- Class-typical GI adverse effects during titration
- Monitor for warning symptoms consistent with incretin labeling
- Review concomitant oral drug timing given delayed gastric emptying
Regulatory context
Branded tirzepatide is FDA-approved for labeled indications. Alternative clinic presentations require compliant sourcing and professional dispensing practices.
Educational formulary information for licensed clinics and practitioners only. PureVital presents professional supplement / wellness formulary items — not regular medicines. Final presentation choice, titration, and monitoring remain clinical decisions. Not intended to diagnose, treat, cure, or prevent any disease.
Continue browsing
Related formulary items
Same category presentations clinics often review together.
Featured
Pen
Featured
PenGLP Weight Loss Pens
Semaglutide Pen (New Super Strength)
21.6mg/ 3ml
PV-SEMAGLUTIDE-PEN-NEW-SUPER-ST-21.6MG3ML
$449.99
Featured
Pen
Featured
Vial